Target intelligence / Profile preview

Tubulointerstitial nephritis antigen like 1 (TINAGL1)

Target
TINAGL1
Molecular classification
Other (matricellular protein), Extracellular matrix protein, Glycoprotein
01

Overview

Tubulointerstitial nephritis antigen like 1 (TINAGL1) is a secreted extracellular matrix glycoprotein with high sequence similarity to tubulointerstitial nephritis antigen (TINAG)[3]. It is localized to basement membranes, especially in renal tubules, where it plays a role in the development and differentiation of renal tubules during nephrogenesis[1][3]. TINAGL1 appears to regulate tubulogenesis, likely by modulating interactions with other matrix proteins such as type IV collagen, laminin, and integrin receptors. Its expression is developmentally regulated in the kidney, and its disruption selectively affects the formation and morphology of tubules, while sparing glomeruli[1]. TINAGL1 is also recognized by antibodies in certain immune-related tubulointerstitial nephritides and has been implicated in promoting bacterial colonization and gastritis in the gastric mucosa[5]. Mutations or altered expression of TINAGL1 have been associated with colorectal adenocarcinoma[3][5]. No approved drugs are currently noted to specifically target TINAGL1, and its value as a direct clinical biomarker or therapeutic target remains under investigation.

Other names
Tubulointerstitial nephritis antigen-like protein 1TINALTubulointerstitial nephritis antigen homolog 1
02

Biological functions

Extracellular matrix organizationRegulation of tubulogenesisModulation of cell adhesionPromotion of tissue remodeling
03

Disease associations

Cancer (Colorectal adenocarcinoma)Inflammation (tubulointerstitial nephritis)Other (gastritis, tissue development)
04

Biomarkers

Antibody reactivity (in tubulointerstitial nephritis)Expression level (possibly in colorectal adenocarcinoma and nephritis)

Beyond the preview

Go deeper on Tubulointerstitial nephritis antigen like 1 (TINAGL1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tubulointerstitial nephritis antigen like 1 (TINAGL1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call